Noema Pharma
Noema Pharma is a clinical-stage biotech company that develops oral small molecule therapeutics.
$112M Series B+ ·
Led by Forbion Capital Partners · Source: fundraisingfox.com
Latest round on record: Series B+, November 2025, amount undisclosed.
Total raised: $171M across 2 sourced rounds
All 4 rounds ↓Signals
About Noema Pharma
These therapeutics are designed to benefit people living with neurological and related disorders, including trigeminal neuralgia and menopause-related symptoms. The company aims to deliver treatments for patients with rare and often-overlooked conditions of the nervous system.
Noema Pharma | 406 days from website to first raise on record
Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | undisclosed | — | fundraisingfox.com | |
| Series B+ | undisclosed | — | fundraisingfox.com | |
| Series B+ | $112M | fundraisingfox.com | ||
| Series A | $59M | globalgenes.org |
Timeline
- Website created
Founders and team
GG
George Garibaldi FounderLC
Luigi Costa FounderAT
Amine Tahiri VP Clinical Development, Adult ProgramsIL
Ilise Lombardo Chief Executive OfficerMG
Michael Gutch Chief Financial OfficerRL
Renata Lazarova VP Clinical Development, Pediatric ProgramsRL
Robert Lasser CMOSN
Sally Nixon Head of OperationsSR
Simon Roitt VP Clinical Operations
Investors
BBioMedPartners
EEQT Life Sciences
FForbion Capital Partnerslead investor
GGilde Healthcare
IInvus
JJeito Capitallead investor
PPolarislead investor
SSofinnova Partnerslead investor
UUPMC Enterprises
Companies like Noema Pharma
CCellCentric$220M Series B+ · May 2026
RRgenta TherapeuticsSeries B+ · Nov 2026
CCity TherapeuticsSeries B+ · Aug 2026
AAlzheon$100M Series B+ · Apr 2022
FFormation Bio$372M Series B+ · Jun 2024
TTrialSpark$156M Series B+ · Oct 2021
Other companies backed by Forbion Capital Partners
OOMass Therapeutics$310M Series B+ · Oct 2026
KKynexis$112.57M Series A · Aug 2026
RRQ Bio$115M Series A · Jun 2026
CCellCentric$220M Series B+ · May 2026
TTropic Biosciences$105M Series B+ · Mar 2026
SSidera Bio$109.99M Series A · Nov 2025
Forbion Capital Partners portfolio →
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/noema-pharma (get a free API key).